Heart Attack Risk Is Nearly 5 Times Higher in the First Hour After Smoking Cannabis ↗
Cannabis elevates heart attack risk 4.8x in the first hour after use — similar to heavy exercise (5.9x) and anger (2.3x) — but the absolute risk is low.
Browse more cannabis research, findings, methods, and limitations.
Cannabis elevates heart attack risk 4.8x in the first hour after use — similar to heavy exercise (5.9x) and anger (2.3x) — but the absolute risk is low.
First large NEJM study to show marijuana use in pregnancy is independently associated with lower birth weight (79g less) and shorter length, after controlling for tobacco, alcohol, and cocaine.
All five major cannabinoids killed MRSA as effectively as vancomycin — opening an unexpected new front in the fight against antibiotic-resistant superbugs.
Beta-caryophyllene from black pepper selectively activates the CB2 cannabinoid receptor — the only terpene confirmed to directly bind a cannabinoid receptor, with anti-inflammatory effects proven in mice.
States with medical marijuana laws had 24.8% fewer opioid deaths — but later data complicated the picture.
Landmark Lancet study ranked 20 drugs by harm: alcohol scored highest (72/100), cannabis placed 8th (20/100). Drug classifications correlated poorly with actual evidence of harm.
The definitive 468-page review: strong evidence for chronic pain and psychosis risk, insufficient evidence for most other claims, and a call to remove research barriers.
CARDIA cohort, 5,115 people, 20 years: cannabis smoking showed a nonlinear pattern — slight lung function improvement at low exposure, leveling off at moderate, trend toward decline only at very high exposure. The opposite of tobacco's linear harm.
Largest case-control study found no cannabis-lung cancer link even in 22,000+ joint users — contradicting the carcinogen hypothesis.
The comprehensive RTI review that documented why edibles cause disproportionate ER visits and established the evidence base for the 10mg standard serving size.
Pivotal Phase III RCT. 572 MS spasticity patients, enriched-enrollment design. 47.6% responded to Sativex in open-label phase. Among randomized responders, Sativex maintained benefit vs placebo deterioration (p=0.0002). Led to approval in 25+ countries.
22 PD patients, open-label. UPDRS motor score improved 30% within 30 minutes of smoking cannabis. Tremor, rigidity, bradykinesia all significantly improved. No control group limits interpretation.
THC at microdoses restored aged mouse brains to young-mouse cognitive and gene expression levels — while impairing young mice.
Legal cannabis access reduced Medicare prescriptions for pain, anxiety, sleep, and seizure medications — saving $165.2 million per year.
Cannabis enhanced opioid pain relief by 27% without increasing opioid blood levels — demonstrating receptor synergy with opioid-sparing potential.
FBI data analysis showed Black Americans arrested for marijuana at 3.73x the rate of white Americans despite similar usage — a disparity that persisted even after a decade of legalization reform.
Nabilone significantly reduced PTSD nightmares in 10 treatment-resistant military veterans, leading the Canadian Armed Forces to adopt cannabinoids for PTSD treatment.
The first controlled trial of CBD for dog arthritis — from Cornell University — found significant pain reduction and activity improvement. Dogs can't placebo, making this unusually clean evidence.
Based on 18,000+ patients, Sulak showed that most cannabis patients use far more than they need — 1-5mg THC often provides better therapeutic results than higher doses, without tolerance buildup.
Medical cannabis reduced monthly migraine frequency from 10.4 to 4.6 in 121 patients — large effect but no placebo control.
First evidence that topical CBD penetrates skin, reduces joint inflammation, and relieves arthritis pain in rats — at specific doses and without CNS effects.
First randomized trial of THC+CBD for brain cancer showed 83% vs 44% one-year survival — encouraging but from only 21 patients. The ARISTOCRAT follow-up trial with 230+ patients is actively recruiting.
The first systematic study of cannabis subjective effects found that 70% of users report enhanced music perception — a finding now explained by THC's effects on auditory processing, attention filtering, and dopamine reward.
Chemical analysis of 2,500-year-old funeral braziers from the Pamir Mountains reveals the earliest evidence of cannabis smoking for psychoactive purposes.
Russo declared the indica/sativa distinction "total nonsense" in this landmark interview, arguing that only chemical testing — cannabinoid and terpene profiles — can meaningfully classify cannabis products.
Endocannabinoid system genes traced back 500+ million years across the animal kingdom — proving the ECS is among the most ancient and essential signaling systems in biology.
Mechoulam's definitive review of how the brain's own cannabis system regulates anxiety, mood, memory, and reward — and why dose determines whether the effect is therapeutic or harmful.
Largest CBD-for-psychosis RCT: 88 patients, 6 weeks. CBD 1000mg/day significantly reduced positive symptoms with zero side effect burden.
Longitudinal study of 505 college students found cannabis predicted reduced initiative and persistence one month later, providing partial support for amotivational syndrome while revealing the effect is modest and selective.
Multi-cohort analysis of 3,765 adolescents found daily cannabis use before 17 was associated with 63% lower high school completion, 18x higher dependence, and 7x higher suicide attempts — after controlling for 53 confounders.
Zero clinical trials support CBN as a sleep aid. Eight human studies found no reliable sedative effects. The "sleepy cannabinoid" label is marketing, not science.
The definitive history of US drug prohibition, documenting how Harry Anslinger's racist propaganda — not pharmacological evidence — produced cannabis criminalization in 1937 and shaped policy for nearly a century.
The founder of cannabinoid chemistry looked back on 41 years and argued that most cannabis compounds remained completely unstudied — a neglected pharmacological treasure trove.
Twenty-year reassessment of the hypothesis that migraine, fibromyalgia, and IBS share underlying endocannabinoid dysfunction — evolved from simple deficiency to nuanced dysregulation model.
Nearly two pounds of cultivated, psychoactive cannabis found in a 2,700-year-old shaman's tomb in China — confirmed by chemical and genetic analysis as the oldest drug-type cannabis specimen ever discovered.
No evidence that cannabis kills brain cells — the myth traces to a debunked 1980 study. Changes are functional and reversible.
Debunked study origin of the kills brain cells myth — monkeys were suffocated, not drugged by cannabis.
Mixing cannabis and alcohol simultaneously doubles drunk driving risk and triples social problems. Keeping them separate is dramatically safer.
Cannabis users may need dramatically more sedation and face higher airway/cardiovascular risk during surgery, but most never tell their surgical team.
The comprehensive review that argued the gateway hypothesis should be replaced by the common liability model: shared genetic and neurobiological risk factors, not cannabis itself, drive drug escalation.
The researchers who discovered cannabis could kill cancer cells in the lab explain the science and warn: preclinical evidence is real but no one should replace proven cancer treatments with cannabis.
Cannabis made running more enjoyable (90.5%), less painful (69%), and more motivating (57%) — without improving performance. CBD worked better than THC for exercise enjoyment.
Cannabis allergy is real — IgE-mediated, potentially serious, cross-reactive with tomatoes and peaches, and rising as exposure increases.
No evidence shows cannabis reduces birth control effectiveness. The enzyme interaction (CYP3A4 inhibition) would theoretically increase contraceptive hormone levels, not decrease them.
Lemberger discovered that the liver converts THC into 11-hydroxy-THC, a metabolite up to 7x more potent — the molecular reason edibles hit harder, last longer, and feel different from smoking.
Di Marzo revealed that the endocannabinoid system is part of a much larger 'endocannabinoidome' — with 20+ receptors and dozens of signaling molecules — explaining why CBD works and why single-target drugs often fail.
NEJM RCT: CBD reduced seizures 39% vs 13% placebo in Dravet syndrome. Led to Epidiolex FDA approval — first cannabis-derived drug.
The Australian twin study that provided the strongest evidence for a cannabis gateway effect: early-using twins were 2-5x more likely to escalate to other drugs.
First study of cannabis and female sexual function found that women who used cannabis before sex had 2.13x the odds of satisfactory orgasm, with the majority reporting improved desire and pleasure.